FDA Approves Eli Lilly's Once-Weekly Insulin, a First for Diabetes Care
The approval marks a major shift in diabetes management, offering a weekly alternative to daily insulin injections.
Medicine & Biotech
Clinical AI, drug discovery, devices, and regulatory approvals.
Kyverna's one-year CAR-T data show sustained efficacy, clean safety
Kyverna's miv-cel maintains efficacy at one year without safety problems, contrasting with rivals' setbacks.
Boehringer, Envisagenics in $1B AI Oncology Target Deal
The multi-year pact pairs Envisagenics' AI platform with Boehringer's validation capabilities to pursue tumor-specific targets.
Former FDA chiefs back Heidi Overton as commissioner pick
Two ex-commissioners argue Overton can strengthen the agency during a turbulent period.
FDA Approves Elevar's Lyrfigtu for Bile Duct Cancer
The approval marks the first time a novel cancer drug from a Korean company has received FDA clearance.
Lilly and InnoCare Strike $100M Upfront, $3.25B Milestone Drug Discovery Deal
Eli Lilly's $100 million upfront payment to InnoCare Pharma could grow to $3.25 billion through milestones in a five-target discovery pact.
New autism committee chair has financial ties to leucovorin
The federal panel that guides roughly $2 billion in autism research is now led by a neurologist with financial links to a drug promoted for autism.
Enveda raises $311M to scale nature-based drug discovery
The series E round backs Enveda's decade-long push to turn its nature-derived drug platform into a widely recognized biotech brand.
European drugmakers urge EU to boost biopharma R&D as US, China race ahead
Nine major pharmaceutical companies warn that Europe is falling behind in innovation and ask the bloc to prioritize research and development.
Pentagon awards Flagship $47M for biodefense countermeasures
Flagship Pioneering lands a Department of Defense contract to develop technologies that counter biological threats, marking a notable federal bet on venture-backed biotech.
Stem Cell Transplants Restore Movement in Mice After Stroke
A study in mice shows stem cell transplants regenerated stroke-damaged brain tissue and restored lost motor function.
Novo Plans Consumer-Style Drug Pipeline; Alkermes Posts Early ADHD Data
Novo says it will look for products that can be marketed more like consumer goods, while Alkermes disclosed early ADHD trial results.
Most Older Adults Would Consider a Dementia Vaccine, Survey Finds
A new USC Schaeffer Center survey suggests strong public appetite among older adults for a preventive dementia vaccine.
White House moves to place NIH grant decisions under political oversight
The Trump administration is reportedly planning an executive order to add political review to NIH funding decisions.
Hundreds of pesticide chemicals linked to breast cancer risk, study finds
A peer-reviewed study by Silent Spring Institute identifies hundreds of chemicals in pesticide products—including many listed as inert—that may raise breast cancer risk.
Roche's sefaxersen phase 3 win sets up kidney disease showdown with Novartis
Roche's phase 3 success for sefaxersen positions the Ionis-partnered candidate to challenge Novartis in the kidney disease market.
Amgen's Phase 3 Sjögren's Drug Succeeds, Boosting Horizon Deal
A phase 3 trial shows Amgen's fusion protein significantly reduces Sjögren's disease severity, offering a rare win for its Horizon Therapeutics acquisition.
Kidney Transplant Access Lags for Patients With Intellectual Disabilities
A Medicare analysis finds that people with end-stage kidney disease and intellectual or developmental disabilities are evaluated for and receive kidney transplants far less often than others, despite legal protections.